Angelica sinensis for Health & Longevity
Evidence Review created on 10/15/2026 using AI4L + evidence-mcp / Gemini 4 Argon
Also known as: Dong Quai, Dang Gui, Danggui, Chinese Angelica, Female Ginseng, Tang Kuei, Toki, Angelica polymorpha var. sinensis
Motivation
Angelica sinensis (Dong Quai, or female ginseng) is an aromatic perennial root native to high-altitude regions of western China. Its dried root contains volatile phthalides, organic phenolic acids such as ferulic acid, and branching polysaccharides that act on vascular tone, blood cell production, and cellular oxidative signaling. Health- and longevity-oriented adults frequently encounter the root in formulations aimed at menopausal comfort, vascular circulation, and kidney preservation.
Recorded in classical Chinese herbal texts for nearly two millennia and introduced to European medicine at the end of the nineteenth century, Angelica sinensis remains one of the most widely consumed botanicals worldwide. While traditional practice pairs the root with other herbs in boiled herbal teas or specialized intravenous hospital preparations, Western dietary supplements typically provide isolated oral root powders or extracts. Clinical investigations have examined whether single-herb oral administration reproduces the effects studied in multi-herb formulas, hospital injections, and national health-registry cohorts.
This review examines the clinical, observational, and mechanistic evidence for Angelica sinensis across kidney preservation, menopausal hot flashes, and red blood cell production, alongside its adverse-event profile, drug interactions, sourcing standards, and dosing protocols.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
The following resources provide an accessible overview of Angelica sinensis phytochemistry, clinical trials, and organ-protective mechanisms.
- A Natural Approach to Menopause - Dale Kiefer
Examines the traditional gynecological use of Angelica sinensis in Traditional Chinese Medicine (TCM) alongside Western clinical trial data showing why single-herb oral supplementation differs from multi-herb menopausal formulations.
- Phytochemical and pharmacological studies on Radix Angelica sinensis - Chen et al., 2013
Comprehensive narrative review detailing over 70 isolated compounds—including Z-ligustilide, ferulic acid, and Angelica sinensis polysaccharides (ASP, complex branching sugar polymers)—and their cardiovascular, neuroprotective, and hematopoietic actions.
- Danggui to Angelica sinensis root: are potential benefits to European women lost in translation? A review - Hook, 2014
Analyzes how traditional root processing (wine-frying, smoke-drying), multi-herb synergy, and European Pharmacopoeia quality standards shape the clinical translation of Angelica sinensis to Western users.
- Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial - Hirata et al., 1997
Landmark 24-week randomized controlled trial (RCT) demonstrating that 4.5 g/day of oral Angelica sinensis root monotherapy acts neither as a clinical phytoestrogen nor as an effective standalone treatment for menopausal hot flashes.
- Dose- and time-dependent renoprotection of Angelica sinensis in patients with chronic kidney disease: A longitudinal cohort study - Chen et al., 2023
Propensity-score-matched cohort of 55,044 chronic kidney disease (CKD) patients evaluating associations between prescribed Angelica sinensis exposure, kidney failure progression, and all-cause mortality.
Dedicated web and on-site searches of Rhonda Patrick (FoundMyFitness), Peter Attia, Andrew Huberman, Chris Kresser, and Lifespan.io returned no articles or podcast episodes covering Angelica sinensis (Dong Quai).
Grokipedia
Overview of Angelica sinensis taxonomy, high-altitude Gansu cultivation, root anatomy, major phytochemical classes (phthalides, coumarins, ferulic acid, and polysaccharides), clinical trial findings, and anticoagulant safety considerations.
Examine
Summarizes supplemental Dong Quai dosing and mechanisms, though its text primarily discusses decursin-rich Korean Angelica gigas rather than Chinese Angelica sinensis, illustrating frequent commercial species conflation.
ConsumerLab
No dedicated ConsumerLab product review or article exists for Angelica sinensis (Dong Quai); site search returns only brief question-and-answer entries and regulatory recall notices.
Systematic Reviews
Systematic reviews and meta-analyses have evaluated Angelica sinensis in menopausal vasomotor (hot flash and night sweat) management, hormone-deprivation hot flashes, fibrotic lung disease, and herbal hepatotoxicity.
- The Effectiveness of Non-Soy Oral Herbal Supplements for Menopausal Symptoms: A Systematic Review - Jing et al., 2026
Evaluated 30 RCTs across 19 herbal interventions, reporting that the trial testing Angelica sinensis monotherapy found no measurable effect on menopausal symptoms.
- Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy - Schaldemose et al., 2026
Systematic review of 35 studies during androgen deprivation therapy (prostate cancer hormone suppression), concluding that oral Angelica sinensis monotherapy is ineffective for hot flashes.
- A systematic review of herbal medicinal products for the treatment of menopausal symptoms - Huntley & Ernst, 2003
Assessed 18 placebo-controlled menopausal trials, concluding that single-herb Angelica sinensis showed no clinical benefit over placebo for vasomotor symptoms.
- Radix Astragali and Radix Angelicae Sinensis in the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis - Zhang et al., 2020
Meta-analysis of 17 RCTs showing Angelica sinensis plus Astragalus improved clinical efficacy and lung function in idiopathic pulmonary fibrosis (IPF, progressive lung scarring).
- Systematic Review on Chinese Herbal Medicine Induced Liver Injury - Zhang et al., 2016
Analyzed 54 causality-graded cases of herbal hepatotoxicity, identifying Angelica sinensis among the six most frequently co-prescribed botanicals in multi-herb liver injury.
Mechanism of Action
Angelica sinensis bioactivity stems from lipophilic alkylphthalides (Z-ligustilide, butylidenephthalide), phenolic acids (ferulic acid), and water-soluble ASP (Chen et al., 2013). In vascular and renal beds, ferulic acid scavenges free radicals, boosts endothelial nitric oxide (NO, a vessel-relaxing signaling molecule), inhibits thromboxane A2 (TXA2, a platelet-clumping vasoconstrictor), and preserves prostacyclin (PGI2, an anti-clumping vasodilator) (Wang & Ou-Yang, 2005). Z-ligustilide activates nuclear factor erythroid 2-related factor 2 (Nrf2, a master antioxidant gene regulator), inhibits nuclear factor kappa B (NF-κB, a pro-inflammatory transcription complex), and suppresses transforming growth factor-beta 1 (TGF-β1, a fibrosis-driving cytokine) (Shen et al., 2024). Meanwhile, ASP stimulates erythropoietin (EPO, the hormone driving red blood cell synthesis) and blocks hepatic hepcidin via bone morphogenetic protein 6 (BMP6, an iron-regulatory protein) and SMAD family member 4 (SMAD4, an intracellular signaling factor) to mobilize iron (Nai et al., 2021).
Competing hypotheses surround its gynecological effects: extracts weakly bind estrogen receptors in vitro (Lau et al., 2005) yet alter neither sex hormones nor uterine tissue in women (Hirata et al., 1997), pointing instead to central 5-hydroxytryptamine receptor 7 (5-HT7, a thermoregulatory serotonin receptor) modulation (Hajirahimkhan et al., 2013). Z-ligustilide crosses the blood-brain barrier (Wu et al., 2014), while oral ferulic acid has 1.25-hour absorption and 2.1-hour elimination half-lives (Luo et al., 2003), and root extracts modulate hepatic cytochrome P450 (CYP, drug-metabolizing liver enzymes) isoforms CYP1A2 (clears caffeine), CYP2C9 (clears warfarin), CYP2D6 (clears beta-blockers), and CYP3A4 (clears many prescription drugs) (Tang et al., 2006).
Historical Context & Evolution
Angelica sinensis was first cataloged around 200 CE in the Shennong Bencao Jing (Divine Farmer’s Classic of Materia Medica) and later detailed in the 1596 Bencao Gangmu, where it was designated the premier blood-tonifying and blood-invigorating root for dysmenorrhea (painful menstrual cramping), amenorrhea (absence of menstruation), postpartum recovery, and anemia (Chen et al., 2013). Classical TCM practitioners rarely administered the root alone; instead, they processed distinct root segments—using the root head (Danggui-tou) for stopping bleeding, main body (Danggui-shen) for nourishing blood, and tail (Danggui-wei) for resolving blood stasis—and paired it in synergistic decoctions such as the 1247 CE formula Danggui Buxue Tang (a 1:5 ratio of Angelica sinensis to Astragalus membranaceus) (Hook, 2014).
The herb entered Western pharmacology in 1899 when the German pharmaceutical firm Merck introduced a standardized liquid extract named Eumenol for menstrual disorders (Hook, 2014). Late-twentieth-century Western supplement marketing reframed Angelica sinensis as a standalone “female ginseng” and natural phytoestrogen alternative to hormone replacement therapy. However, when a 1997 placebo-controlled trial in 71 postmenopausal women found that 4.5 g/day of isolated Angelica sinensis root neither altered estradiol or endometrial thickness nor relieved hot flashes (Hirata et al., 1997), scientific focus shifted away from single-herb estrogenic claims. Subsequent clinical and translational research pivoted toward multi-herb vasomotor synergy (Haines et al., 2008), hospital intravenous preparations for ischemic stroke and pulmonary hypertension (Liu et al., 2004), and long-term renal protection in chronic kidney disease (Chen et al., 2023).
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: human RCTs of oral Angelica sinensis monotherapy have not replicated improvements in validated clinical endpoints across independent research groups, as positive trials have tested multi-herb combinations, intravenous injections, or single observational cohorts.
Medium 🟩 🟩
Renal Preservation and Survival in Chronic Kidney Disease
Oral Angelica sinensis is associated with slower kidney function decline and lower mortality in CKD via antifibrotic TGF-β1 suppression, antioxidant Nrf2 activation, and improved renal microcirculation (Chen et al., 2023). In a propensity-score-matched nationwide cohort of 55,044 Taiwanese CKD patients (18,348 new users vs. 36,696 non-users) excluding confounding herbs (Astragalus, Rheum, Salvia), cumulative exposure dose-dependently lowered progression to end-stage renal disease (ESRD, advanced kidney failure requiring dialysis or transplant) and death. Because observational registry data leave residual confounding, the evidence is graded Medium.
Magnitude: Associated with a 23% lower risk of ESRD with an adjusted hazard ratio (aHR, relative event rate over time adjusted for confounders) of 0.77 and a 95% confidence interval (CI, range within which the true effect likely falls) of 0.69–0.86, plus a 45% lower risk of all-cause mortality (aHR 0.55, 95% CI 0.53–0.57) versus non-users (Chen et al., 2023).
Low 🟩
Menopausal and Hormonal Vasomotor Symptom Relief ⚠️ Conflicted
Monotherapy failed in 71 women (Hirata et al., 1997) and 22 men (Al-Bareeq et al., 2010). Indirect multi-herb RCTs—Climex (Kupfersztain et al., 2003), Danggui Buxue Tang for mild flushes (Haines et al., 2008), and SupHerb-funded Phyto-Female Complex (Rotem & Kaplan, 2007)—showed benefit. Net reading: monotherapy fails; multi-herb formulas reduce flushes.
Magnitude: Monotherapy showed no difference from placebo in hot flashes or Kupperman Index (a validated menopausal symptom scale) (Hirata et al., 1997), whereas indirect multi-herb Climex reduced 12-week hot flushes by 90–96% versus 15–25% with placebo (Kupfersztain et al., 2003) and 6.0 g/day Danggui Buxue Tang improved Greene Climacteric Scale scores more than 1.5 g/day (Wang et al., 2013).
Erythropoiesis, Iron Homeostasis, and Aerobic Recovery
Angelica sinensis stimulates EPO synthesis and suppresses hepcidin to mobilize iron (Nai et al., 2021). Human evidence rests on an uncontrolled case report reversing EPO-resistant renal anemia (Bradley et al., 1999) and an indirect 36-runner RCT testing Danggui Buxue Tang (Angelica sinensis plus Astragalus) (Chang et al., 2018).
Magnitude: Indirect 11-day Danggui Buxue Tang supplementation shortened 13-km run times by 14.0% (12.3 minutes faster than placebo) and raised post-exercise serum iron by 63.3% versus placebo (Chang et al., 2018).
Neurofunctional Recovery in Acute Ischemic Stroke
Ferulic acid and Z-ligustilide inhibit platelet aggregation and protect ischemic neurons (Wang & Ou-Yang, 2005). In a 1,404-patient trial, 25% Angelica sinensis injection improved post-stroke neurological recovery and infarct volume (Liu et al., 2004); evidence is indirect because intravenous hospital injection differs in route from oral use.
Magnitude: Intravenous Angelica sinensis achieved a 78.7% total clinical effective rate, exceeding compound Salvia (63.6%) by 15.1 percentage points and dextran (59.3%) by 19.4 percentage points (Liu et al., 2004).
Pulmonary Hemodynamics and Fibrosis Attenuation
Angelica sinensis inhibits hypoxic pulmonary vasoconstriction and TGF-β1 lung fibrosis (Zhang et al., 2020). Evidence is indirect, resting on an intravenous Angelica sinensis RCT in 60 chronic obstructive pulmonary disease (COPD, airflow-obstructing lung disease) patients (Xu & Li, 2000) and an IPF meta-analysis with Astragalus (Zhang et al., 2020).
Magnitude: Intravenous Angelica sinensis reduced mean pulmonary arterial pressure by 18 ± 5% and pulmonary vascular resistance by 27 ± 8% versus insignificant change in glucose control (not compared between groups; Xu & Li, 2000); combined Angelica–Astragalus therapy improved IPF clinical efficacy (risk ratio [RR, ratio of event probabilities between groups] 1.28, 95% CI 1.20–1.37; Zhang et al., 2020).
Ejaculatory Latency in Premature Ejaculation ⭕️ Not Central to Health & Longevity
Bears on male sexual function rather than longevity via penile sensory desensitization. A Phase III RCT in 106 men showed topical SS-cream prolongs ejaculatory latency (Choi et al., 2000); evidence is indirect because SS-cream is a topical nine-herb formulation rather than oral Angelica sinensis.
Magnitude: Topical 0.2 g SS-cream prolonged mean ejaculatory latency to 10.92 ± 0.95 minutes versus 2.45 ± 0.29 minutes with placebo (8.47 minutes longer than placebo; Choi et al., 2000).
Speculative 🟨
Chondroprotection and Osteoarthritis Attenuation
ASP and ferulic acid activate chondrocyte autophagy and inhibit cartilage-degrading enzymes. Evidence comes strictly from rodent osteoarthritis models and cultured human chondrocytes without human clinical trials (Xu et al., 2021; Magdalou et al., 2015).
Neuroprotection Against Amyloid and Ischemic Brain Injury
Volatile oil and Z-ligustilide reduce amyloid-beta toxicity and inhibit neuronal apoptosis. Evidence is restricted to nematode, rodent, and cell-culture models without human dementia trials (Wang et al., 2025; Long et al., 2022).
Benefit-Modifying Factors
-
Genetic polymorphisms: Variants in iron-regulatory genes—hepcidin antimicrobial peptide (HAMP, the gene encoding iron-blocking hepcidin) and transmembrane serine protease 6 (TMPRSS6, a protease gene suppressing hepcidin)—theoretically modify blood-building response to ASP (Nai et al., 2021).
-
Baseline biomarker levels: Renoprotective and blood-building benefits are greatest in individuals with reduced baseline estimated glomerular filtration rate (eGFR, blood-based kidney filtering speed) or low serum iron (Chen et al., 2023; Bradley et al., 1999).
-
Sex-based differences: Oral monotherapy fails for hot flashes in both women (Hirata et al., 1997) and men (Al-Bareeq et al., 2010), whereas CKD survival and endurance iron-recovery benefits occur across sexes (Chen et al., 2023; Chang et al., 2018).
-
Pre-existing health conditions: Renoprotective and blood-building effects are documented primarily in patients with pre-existing CKD, EPO-resistant anemia, or exercise-induced iron depletion rather than healthy adults (Chen et al., 2023; Bradley et al., 1999).
-
Age-related considerations: In the Taiwanese CKD cohort, significant reductions in all-cause mortality with Angelica sinensis were observed across both adults younger than 65 years and older adults aged 65 years or above (Chen et al., 2023).
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: human adverse events are documented only in single case reports, multi-herb hepatotoxicity series, or single trials rather than replicated controlled trials across independent research groups.
Medium 🟥 🟥
No risk reaches Medium: controlled human trials of oral Angelica sinensis monotherapy have found no statistically significant excess adverse events compared with placebo.
Low 🟥
Anticoagulant Potentiation and Bleeding Risk ⚠️ Conflicted
Coumarins inhibit platelets, and warfarin co-administration doubled clotting times in one case (Page & Lawrence, 1999). Conversely, an aspirin crossover RCT (Fung et al., 2017) and antiplatelet cohort (Tsai et al., 2017) found no excess bleeding. Net reading: antiplatelet co-administration is safe, while warfarin potentiation remains possible.
Magnitude: Warfarin co-administration doubled prothrombin time (PT, blood clotting speed test) and international normalized ratio (INR, standardized PT ratio) in one case (no control group; Page & Lawrence, 1999), whereas antiplatelets showed no excess bleeding (odds ratio [OR, ratio of event odds between groups] 1.00, 95% CI 0.51–1.95; Tsai et al., 2017) or change in PT and activated partial thromboplastin time (aPTT, intrinsic clotting pathway test) (Fung et al., 2017).
Mild Gastrointestinal Symptoms ⚠️ Conflicted
Clinical monographs note mild bloating or eructation (belching) from volatile phthalides after oral Angelica sinensis (Hardy, 2000). However, in a 24-week RCT of 71 women taking 4.5 g/day, gastrointestinal symptoms did not exceed placebo (Hirata et al., 1997). Net reading: mild gastrointestinal complaints occur no more frequently than placebo.
Magnitude: In a 24-week RCT, eructation occurred in 22.9% of the Angelica sinensis group versus 31.4% of the placebo group (8.5 percentage points lower than placebo; Hirata et al., 1997).
Herb-Induced Liver Injury
Idiosyncratic liver injury has occurred with multi-herb TCM formulas containing Angelica sinensis (Zhang et al., 2016). Across 54 cases graded by the Roussel Uclaf Causality Assessment Method (RUCAM, a clinical liver-injury scale), Angelica sinensis was among the six most frequent herbs; evidence is indirect because cases involved multi-herb mixtures.
Magnitude: Across 54 RUCAM-graded multi-herb hepatotoxicity cases (no control group), median latency was 30 days, 81.48% presented as hepatocellular injury, 96.3% recovered after cessation, and 1.85% (1 case) was fatal (Zhang et al., 2016).
Gynecomastia and Estrogenic Tissue Stimulation ⚠️ Conflicted
A case report described male gynecomastia (benign breast enlargement) after commercial Dong Quai tablets (Goh & Loh, 2001). Conversely, a 24-week RCT in 71 women found no change in estradiol or endometrial thickness (Hirata et al., 1997). Net reading: authenticated Angelica sinensis does not stimulate estrogenic tissue in trials.
Magnitude: Over 24 weeks, 4.5 g/day oral Angelica sinensis produced no significant difference versus placebo in endometrial thickness, vaginal maturation index, estrone, estradiol, or sex hormone-binding globulin (SHBG, a protein regulating bioavailable sex hormones) (Hirata et al., 1997).
Local Cutaneous Burning and Mild Pain (Topical Formulations)
Topical application of Angelica sinensis extracts within the nine-herb SS-cream formulation causes transient local penile burning and mild pain via local vasodilatory irritation (Choi et al., 2000). Evidence is graded Low and is indirect because the adverse event reflects a topical nine-herb cream rather than oral Angelica sinensis.
Magnitude: In a Phase III RCT, mild local burning or pain occurred in 18.49% (98 of 530) of active topical SS-cream applications (no comparison group rate reported for placebo; not compared between groups; Choi et al., 2000).
Transient Blood Pressure Elevation
Isolated clinical case reports cited in perioperative safety reviews have noted transient blood pressure elevation in individuals consuming Angelica sinensis preparations, resolving after discontinuation (Jalili et al., 2013). Evidence is graded Low because it rests on isolated uncontrolled case reports rather than controlled trials.
Magnitude: Not quantified in available studies. Only isolated clinical case reports without a comparison group have described transient blood pressure elevation (Jalili et al., 2013).
Speculative 🟨
Furocoumarin-Mediated Photosensitivity and Phototoxicity
Root trace furocoumarins (psoralen derivatives such as bergapten and xanthotoxin) cross-link skin DNA under ultraviolet light. This mechanism creates a theoretical phototoxicity risk without confirmed clinical cases (Page & Lawrence, 1999; Hook, 2014).
Hormone-Receptor-Positive Breast Cancer Cell Proliferation
Angelica sinensis extracts stimulated MCF-7 (human estrogen-sensitive breast cancer cell line) growth in vitro. Although trials show no uterine estrogenicity, this raises a theoretical hormone-sensitive tumor risk (Lau et al., 2005; Hirata et al., 1997).
Risk-Modifying Factors
-
Genetic polymorphisms: Slow-metabolizer CYP2C9 variants and vitamin K epoxide reductase complex subunit 1 (VKORC1, the warfarin target enzyme recycling vitamin K) variants heighten warfarin bleeding risk with Angelica sinensis (Page & Lawrence, 1999; Tang et al., 2006).
-
Baseline biomarker levels: Elevated baseline INR (>3.0) on warfarin or elevated alanine aminotransferase (ALT, liver injury enzyme) and aspartate aminotransferase (AST, liver and muscle enzyme) increase bleeding and liver risk (Page & Lawrence, 1999; Zhang et al., 2016).
-
Sex-based differences: Uterine contractile modulation and theoretical hormone-sensitive breast or endometrial proliferation risks apply primarily to females (Hook, 2014; Lau et al., 2005), whereas rare supplement-associated gynecomastia has been reported in males (Goh & Loh, 2001).
-
Pre-existing health conditions: Peptic ulcer disease, bleeding disorders, hormone-receptor-positive malignancies, and pre-existing chronic liver disease elevate the potential severity of anticoagulant, proliferative, or hepatic adverse events (MSKCC, 2023; Zhang et al., 2016).
-
Age-related considerations: Older adults experience higher polypharmacy rates with anticoagulants and CYP-metabolized medications, increasing herb–drug interaction vulnerability despite favorable observational survival in CKD patients aged 65 and older (Tsai et al., 2017; Chen et al., 2023).
Key Interactions & Contraindications
-
Vitamin K antagonist anticoagulants (warfarin, acenocoumarol): Caution / avoid unless monitored; human case data show Angelica sinensis doubled PT/INR in a stabilized warfarin patient (Page & Lawrence, 1999). Mitigate by avoiding co-administration or checking INR within 5–7 days of starting or stopping.
-
Antiplatelet agents (aspirin, clopidogrel, ticagrelor): Monitor; although ferulic acid inhibits platelets in vitro, a human crossover RCT with 100 mg/day aspirin (Fung et al., 2017) and a national cohort (Tsai et al., 2017) found no excess bleeding or coagulation changes at standard doses.
-
Direct oral anticoagulants (DOACs, targeted factor Xa or thrombin inhibitors; apixaban, rivaroxaban, dabigatran) and heparins (enoxaparin): Caution (theoretical); preclinical CYP3A4/P-glycoprotein (P-gp, an intestinal and brain drug-efflux pump) modulation and antiplatelet activity could increase bleeding risk (MSKCC, 2023).
-
Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs, pain relievers that block platelet cyclooxygenase; ibuprofen, naproxen) and selective serotonin reuptake inhibitors (SSRIs, antidepressants that impair platelet serotonin uptake; sertraline, fluoxetine): Monitor (theoretical); additive platelet inhibition may increase mucosal bruising (Drugs.com, 2025).
-
Selective estrogen receptor modulators (SERMs, tissue-selective estrogen blockers/activators; tamoxifen, raloxifene) and aromatase inhibitors (AIs, drugs blocking estrogen synthesis; letrozole, anastrozole): Avoid (theoretical); Angelica sinensis extracts stimulated MCF-7 breast cancer cells in vitro and may antagonize endocrine therapy (Lau et al., 2005).
-
Cytochrome P450 CYP2D6 and CYP3A4 substrates (metoprolol, midazolam, atorvastatin) and CYP1A2 substrates (caffeine, theophylline): Monitor (theoretical); rat hepatic microsome studies show Angelica sinensis extracts alter CYP2D6, CYP3A4, and CYP1A2 activity, potentially shifting plasma drug levels (Tang et al., 2006).
-
Anticoagulant or antiplatelet supplements (Ginkgo biloba, Panax ginseng, garlic, Salvia miltiorrhiza): Monitor (theoretical); combining with eicosapentaenoic and docosahexaenoic acids (EPA/DHA, marine omega-3 fatty acids) or antiplatelet herbs may cause additive TXA2 and platelet inhibition (Scott & Elmer, 2002; Drugs.com, 2025).
-
Photosensitizing agents and ultraviolet light therapy (Hypericum perforatum [St. John’s wort], doxycycline, isotretinoin): Caution (theoretical); trace furocoumarins in Angelica sinensis root may cause additive cutaneous phototoxicity during intense ultraviolet exposure (Hook, 2014).
Populations who should avoid Angelica sinensis:
-
Pregnant and breastfeeding women: Contraindicated during pregnancy due to uterine muscle effects and potential teratogenicity, and avoided during lactation due to insufficient infant safety data (Hook, 2014; Drugs.com, 2025).
-
Individuals with hormone-sensitive malignancies or conditions: Patients with estrogen-receptor-positive breast, endometrial, or ovarian cancer, endometriosis, or uterine fibroids should avoid use due to in vitro MCF-7 cell proliferation (Lau et al., 2005; MSKCC, 2023).
-
Patients scheduled for elective surgery or with active bleeding disorders: Discontinue at least 2 weeks prior to surgery to prevent perioperative bleeding or blood pressure fluctuations (Jalili et al., 2013; Drugs.com, 2025).
-
Individuals with active liver injury or decompensated cirrhosis: Avoid use given multi-herb RUCAM-assessed hepatotoxicity reports involving Angelica sinensis (Zhang et al., 2016).
Risk Mitigation Strategies
Doses, timings, and monitoring intervals below follow common practice unless cited.
-
Perioperative washout window: Discontinue all oral Angelica sinensis preparations at least 14 days before scheduled surgery or dental extraction to mitigate perioperative bleeding and blood pressure fluctuations (Jalili et al., 2013; Drugs.com, 2025).
-
Coagulation monitoring on warfarin: Avoid combining with warfarin; if co-administered under medical supervision, check PT/INR within 5–7 days and stop use if INR rises above the target therapeutic range (Page & Lawrence, 1999).
-
Hepatic transaminase surveillance: Measure ALT and AST at baseline and after 4 weeks—near the 30-day median latency of herbal liver injury—and discontinue immediately if ALT exceeds 3× the upper limit of normal (Zhang et al., 2016).
-
With-meal split dosing: Administer capsules or decoctions in 2–3 divided doses with meals to buffer volatile phthalide oils and minimize eructation and mild gastrointestinal discomfort (Hirata et al., 1997).
-
Ultraviolet photoprotection: Apply broad-spectrum sunscreen with sun protection factor (SPF, ultraviolet B protection rating) 30+ and avoid prolonged midday ultraviolet exposure during high-dose supplementation to prevent theoretical furocoumarin-induced phototoxicity (Hook, 2014).
Therapeutic Protocol
Timing, cycling, and titration parameters below follow common practice unless cited.
-
Standard oral root monotherapy: Clinical trials use 1,000 mg/day of granulated extract (Fung et al., 2017) up to 4,500 mg/day of root (Hirata et al., 1997), while decoctions use 3,000–15,000 mg/day (Hook, 2014).
-
Synergistic Danggui Buxue Tang protocol: Integrative TCM regimens combine Angelica sinensis and Astragalus membranaceus (1:5 ratio) at 3,000 mg/day for hot flashes (Haines et al., 2008) or 7,500 mg/day for endurance recovery (Chang et al., 2018).
-
Standardized multi-herb menopausal extracts: Commercial integrative protocols use 400 mg/day of Phyto-Female Complex (containing 100 mg Angelica sinensis root extract standardized to 1% Z-ligustilide, manufactured by SupHerb) (Rotem & Kaplan, 2007).
-
Expected half-life in the body: Oral ferulic acid exhibits a 1.25-hour absorption half-life and a 2.1-hour plasma elimination half-life in preclinical pharmacokinetic models (Luo et al., 2003), while lipophilic Z-ligustilide undergoes rapid systemic clearance (Wu et al., 2014).
-
Single versus split dosing and timing: Because ferulic acid and phthalides clear rapidly, protocols split the daily total into 2–3 doses taken with morning, midday, and evening meals (Hirata et al., 1997; Rotem & Kaplan, 2007).
-
Genetic polymorphisms: Carriers of slow-metabolizer CYP2C9 or VKORC1 variants face heightened coumarin and CYP-mediated bleeding risk (Tang et al., 2006), warranting avoidance with anticoagulants or conservative 1,000 mg/day clinical trial dosing (Fung et al., 2017).
-
Sex-based protocol adjustments: Women typically pause administration during active menstrual bleeding to avoid heavier flow (Hook, 2014), whereas men and postmenopausal women use continuous daily schedules (Chang et al., 2018; Hirata et al., 1997).
-
Age, baseline labs, and pre-existing conditions: CKD patients benefit from cumulative exposures exceeding 30–90 defined daily doses (Chen et al., 2023), initiated at 1,000 mg/day (500 mg twice daily; Al-Bareeq et al., 2010) after baseline INR and liver testing.
Discontinuation & Cycling
-
Duration of use: Short-term courses (11 days to 24 weeks) are used for exercise recovery or vasomotor trials (Chang et al., 2018; Hirata et al., 1997), while multi-month courses show the strongest renoprotection in CKD (Chen et al., 2023).
-
Withdrawal effects: No physiological dependence, rebound hypertension, or endocrine withdrawal syndrome has been reported upon abrupt cessation of oral Angelica sinensis in clinical trials (Hirata et al., 1997; Fung et al., 2017).
-
Tapering protocol: Tapering is unnecessary when discontinuing Angelica sinensis monotherapy; however, if co-administered with warfarin, stopping the herb requires an INR recheck within 1 week as anticoagulant potentiation subsides (Page & Lawrence, 1999).
-
Cycling schedules: Premenopausal women traditionally cycle off Angelica sinensis during the 4–7 days of active menses to prevent menorrhagia (abnormally heavy menstrual bleeding), while non-menstruating users take 1–2 week breaks every 12 weeks (Hook, 2014).
Sourcing and Quality
-
Botanical species authentication: Verify the label specifies Angelica sinensis (Oliv.) Diels root; commercial “Dong Quai” supplements frequently substitute Japanese Angelica acutiloba or Korean Angelica gigas, which contain pyranocoumarins (decursin) and differ pharmacologically (Hook, 2014).
-
Phytochemical standardization: Select extracts standardized to European and Chinese Pharmacopoeia marker thresholds—at least 0.05% trans-ferulic acid (water-soluble marker) and 0.6–1.0% Z-ligustilide (volatile oil marker)—to ensure bioactive potency (Hook, 2014; Chen et al., 2013).
-
Sulfur-free processing: Avoid roots bleached via post-harvest sulfur dioxide fumigation, which degrades ferulic acid, Z-ligustilide, and polysaccharides while leaving sulfite residues; choose shade-dried or sun-dried Minxian Gansu root (Hook, 2014).
-
Heavy metal and contaminant testing: Root crops bioaccumulate soil lead, cadmium, and arsenic; require certificates of analysis or third-party testing from United States Pharmacopeia (USP), NSF International, or Eurofins, and favor practitioners-grade granules (e.g., Kaiser Pharmaceutical, Nong’s, Sun Ten).
Practical Considerations
-
Time to effect: Exercise iron mobilization appears within 11 days (Chang et al., 2018), multi-herb vasomotor relief emerges within 4–12 weeks (Rotem & Kaplan, 2007), and CKD renoprotection requires cumulative use exceeding 30–90 days (Chen et al., 2023).
-
Common pitfalls: Using oral Angelica sinensis monotherapy expecting estrogenic hot-flash relief (Hirata et al., 1997), purchasing unauthenticated Angelica gigas substitutes, or boiling uncovered decoctions for prolonged periods, which volatilizes and destroys Z-ligustilide (Hook, 2014).
-
Regulatory status: Regulated as an over-the-counter dietary supplement in the United States under the Dietary Supplement Health and Education Act (Scott & Elmer, 2002) and recognized as an official pharmacopoeial herbal drug in the Chinese and European Pharmacopoeias (Hook, 2014).
-
Cost and accessibility: Oral capsules, concentrated granules, and raw roots are inexpensive ($10–$30 per month) and widely accessible, whereas hospital-grade 25% intravenous Angelica sinensis injections used in Chinese stroke trials (Liu et al., 2004) are unavailable in Western outpatient settings.
Interaction with Foundational Habits
-
Sleep: Indirectly supportive in multi-herb formulas; while monotherapy does not alter sleep, combining Angelica sinensis in Phyto-Female Complex reduced nocturnal awakenings and improved sleep quality in perimenopausal women by suppressing night sweats (Rotem & Kaplan, 2007). Administer the final split dose with dinner.
-
Nutrition: Potentiating interaction with dietary iron absorption; ASP suppresses hepatic hepcidin via BMP6/SMAD4 inhibition (Nai et al., 2021), enhancing intestinal uptake of heme and non-heme iron. Pair doses with iron- and vitamin C-rich meals while separating from calcium or tannin-rich tea.
-
Exercise: Potentiating interaction with endurance training; 7.5 g/day of Danggui Buxue Tang before a 13-km race boosted post-exercise serum iron by 63.3% and shortened finish time by 14.0% without blunting training adaptations (Chang et al., 2018), supporting Zone 2 training (steady aerobic exercise) and high-intensity interval training (HIIT, alternating maximal sprints with recovery).
-
Stress management: Indirect interaction; Z-ligustilide and ferulic acid attenuate neuroinflammation and modulate central 5-HT7 serotonergic receptors (Hajirahimkhan et al., 2013; Shen et al., 2024), though no human trial has quantified salivary or serum cortisol changes.
Monitoring Protocol & Defining Success
Before starting Angelica sinensis, obtain baseline laboratory testing covering kidney function (eGFR and serum creatinine), iron status and hematology (complete blood count with hemoglobin, serum iron, and ferritin), liver transaminases (ALT and AST), and coagulation (PT/INR if taking anticoagulants). Recheck liver enzymes and iron markers at 4 weeks—matching the 30-day median latency for herbal liver injury (Zhang et al., 2016)—and subsequently every 3–6 months during ongoing supplementation. If co-administered with warfarin, check PT/INR within 5–7 days of starting or stopping (Page & Lawrence, 1999). Serum estradiol is omitted because oral Angelica sinensis does not alter it (Hirata et al., 1997). Track these biomarkers and qualitative markers:
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| eGFR | ≥90 mL/min/1.73 m² (standard reference range) | Expected-change marker: tracks renal preservation and CKD slope (Chen et al., 2023) | Calculate from fasting serum creatinine and cystatin C; track individual trajectory in CKD. |
| Hemoglobin & Serum Iron | Hemoglobin: 13.5–17.5 g/dL men, 12.0–15.5 g/dL women (standard reference range); Serum iron: 60–170 µg/dL (standard reference range) | Expected-change marker: evaluates blood-building and iron-mobilizing response (Chang et al., 2018) | Draw morning fasting blood; pair with serum ferritin and transferrin saturation. |
| ALT & AST | ALT: 7–56 U/L (standard reference range); AST: 8–33 U/L (standard reference range) | Safety check: detects idiosyncratic herb-induced liver injury (Zhang et al., 2016) | Recheck at 4 weeks and every 3–6 months; stop immediately if >3× upper limit of normal. |
| PT / INR | INR 0.8–1.1 (standard reference range) | Safety check: detects anticoagulant potentiation (Page & Lawrence, 1999) | Essential within 5–7 days if co-administered with vitamin K antagonists; maintain prescribed target on warfarin. |
| Blood Pressure | No established target; track change from individual baseline | Safety check: screens for rare transient blood pressure elevation (Jalili et al., 2013) | Measure seated resting blood pressure at baseline and during the first 2 weeks. |
-
Vasomotor symptom diary: Track daily hot-flash and night-sweat frequency with multi-herb formulas (Rotem & Kaplan, 2007).
-
Aerobic recovery: Monitor post-exercise exertion and pace recovery (Chang et al., 2018).
-
Tolerance: Watch for bruising, gingival bleeding, eructation, or dark urine.
Emerging Research
-
Phase II/III recurrent glioblastoma trial (NCT07349693): Not-yet-recruiting randomized trial in 175 recurrent glioblastoma patients comparing intracerebral Angelica sinensis-derived butylidenephthalide (Cerebraca wafer) plus temozolomide against temozolomide alone; positive survival results would validate human neuro-oncological efficacy, whereas null results would refute preclinical glioma findings (Harn et al., 2011).
-
Active Phase I oral butylidenephthalide trial (NCT03651349): Active-not-recruiting randomized trial in 56 healthy volunteers evaluating safety, pharmacokinetics, and maximum tolerated dose of oral Angelica sinensis-derived Z-butylidenephthalide (HK-001) for amyotrophic lateral sclerosis (ALS, progressive motor neuron degeneration); positive safety results would enable neuroprotective trials, whereas dose-limiting toxicity would constrain systemic dosing.
-
Completed unpublished glioblastoma trial (NCT03234595): Phase I/IIa trial in 22 recurrent high-grade glioma patients testing intracerebral Angelica sinensis-derived butylidenephthalide (Cerebraca wafer; Harn et al., 2011) plus temozolomide completed in 2024 with no results posted, leaving human neuro-oncological efficacy unconfirmed.
-
Hepcidin-targeted iron regulation and chondroprotection: Preclinical advances showing ASP suppresses hepcidin (Nai et al., 2021) and activates chondrocyte autophagy (Xu et al., 2021) could expand longevity applications if validated in monotherapy RCTs, whereas negative human trials would confine these mechanisms to preclinical models.
-
Oncogenic receptor proliferation and adulteration risks: Further human tissue studies examining estrogen-receptor-positive breast cell stimulation (Lau et al., 2005) and RUCAM-graded hepatotoxicity from sulfur-fumigated or adulterated roots (Zhang et al., 2016) could narrow the safety margin for long-term supplementation.
Conclusion
Angelica sinensis is a classical Chinese medicinal root rich in volatile phthalides, ferulic acid, and branching polysaccharides that act on blood vessel linings, iron-regulatory signaling, and tissue-scarring pathways. Across the human evidence base, a sharp divide separates standalone oral root supplements from traditional multi-herb formulations and hospital intravenous preparations.
For oral single-herb use, the strongest human evidence comes from a nationwide chronic kidney disease cohort linking cumulative Angelica sinensis exposure to lower rates of kidney failure and mortality. Conversely, randomized trials in postmenopausal women and hormone-deprived men demonstrate that oral Angelica sinensis alone neither alters sex hormones nor relieves hot flashes. Clinical benefits for menopausal hot flashes and night sweats, endurance iron recovery, lung scarring, and clot-related stroke derive from indirect evidence—either multi-herb combinations (including one trial funded by supplement manufacturer SupHerb), topical nine-herb creams, or high-dose intravenous injections—limiting their certainty for standalone oral users.
Oral Angelica sinensis is well tolerated in controlled trials, where mild digestive complaints and blood-thinning bleeding rates match placebo. However, documented excessive blood thinning with warfarin, multi-herb liver injury reports, laboratory cell-culture stimulation of hormone-sensitive breast cancer cells, and frequent commercial substitution with other Angelica species remain key considerations for risk-aware longevity protocols.